52 related articles for article (PubMed ID: 7521786)
1. Interleukin-6 and renal cell cancer: production, regulation, and growth effects.
Koo AS; Armstrong C; Bochner B; Shimabukuro T; Tso CL; deKernion JB; Belldegrum A
Cancer Immunol Immunother; 1992; 35(2):97-105. PubMed ID: 1596939
[TBL] [Abstract][Full Text] [Related]
2. Induction of growth factor-receptor and metalloproteinase genes by epidermal growth factor and/or transforming growth factor-alpha in human gastric carcinoma cell line MKN-28.
Yoshida K; Tsujino T; Yasui W; Kameda T; Sano T; Nakayama H; Toge T; Tahara E
Jpn J Cancer Res; 1990 Aug; 81(8):793-8. PubMed ID: 2168868
[TBL] [Abstract][Full Text] [Related]
3. Altered NCR3 Splice Variants May Result in Deficient NK Cell Function in Renal Cell Carcinoma Patients.
Wang X; Huang L; Wen X; Li D; Yang G; Zheng J
In Vivo; 2024; 38(1):174-183. PubMed ID: 38148073
[TBL] [Abstract][Full Text] [Related]
4. In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.
Jahn B; Brieger J; Fenchel K; Mitrou PS; Bergmann L
Cancer Immunol Immunother; 1994 May; 38(5):304-10. PubMed ID: 8162612
[TBL] [Abstract][Full Text] [Related]
5. YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α.
Takeuchi A; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Dejima T; Tanaka S; Itsumi M; Eto M; Naito S
Cancer Immunol Immunother; 2013 Mar; 62(3):517-27. PubMed ID: 23052245
[TBL] [Abstract][Full Text] [Related]
6. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha.
Ozawa S; Shinohara H; Kanayama HO; Bruns CJ; Bucana CD; Ellis LM; Davis DW; Fidler IJ
Neoplasia; 2001; 3(2):154-64. PubMed ID: 11420751
[TBL] [Abstract][Full Text] [Related]
7. Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-gamma production of lymphocytes.
Ikemoto S; Wada S; Kamizuru M; Hayahara N; Kishimoto T; Maekawa M
Cancer Immunol Immunother; 1992; 34(5):289-93. PubMed ID: 1540974
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha and transforming growth factor-beta co-induce growth inhibition of human tumor cells.
Foser S; Redwanz I; Ebeling M; Heizmann CW; Certa U
Cell Mol Life Sci; 2006 Oct; 63(19-20):2387-96. PubMed ID: 16988787
[TBL] [Abstract][Full Text] [Related]
9. Direct and indirect effects of human interferon alpha on renal cell carcinoma: a new in vitro assay system for evaluating cytokine-mediated antitumor effects.
Matsuyama H; Yoshihiro S; Ohmoto Y; Yamamoto N; Naito K
Cancer Immunol Immunother; 1993 Jul; 37(2):84-8. PubMed ID: 8319245
[TBL] [Abstract][Full Text] [Related]
10. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma.
Yoon KJ; Phelps DA; Bush RA; Remack JS; Billups CA; Khoury JD
PLoS One; 2008; 3(11):e3629. PubMed ID: 18978946
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.
Bielefeldt-Ohmann H; Marzo AL; Himbeck RP; Jarnicki AG; Robinson BW; Fitzpatrick DR
Cancer Immunol Immunother; 1995 Apr; 40(4):241-50. PubMed ID: 7750122
[TBL] [Abstract][Full Text] [Related]
12. A1CF Binding to the p65 Interaction Site on NKRF Decreased IFN-β Expression and p65 Phosphorylation (Ser536) in Renal Carcinoma Cells.
Liu Y; Yang J; Weng D; Xie Y
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612387
[TBL] [Abstract][Full Text] [Related]
13. Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling.
Mizumori O; Zembutsu H; Kato Y; Tsunoda T; Miya F; Morizono T; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Akaza H; Nakamura Y
Exp Ther Med; 2010 Nov; 1(6):955-961. PubMed ID: 22993625
[TBL] [Abstract][Full Text] [Related]
14. New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future.
Dell'Atti L; Bianchi N; Aguiari G
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892875
[TBL] [Abstract][Full Text] [Related]
15. Trim24 prompts tumor progression via inducing EMT in renal cell carcinoma.
Jiang T; Mao H; Chen Q; Cao L; He Y; Gao X; Chen W; Zhang H
Open Med (Wars); 2020; 15(1):1153-1162. PubMed ID: 33336072
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder.
Milella M; Jacobelli J; Cavallo F; Guarini A; Velotti F; Frati L; Foà R; Forni G; Santoni A
Br J Cancer; 1999 Feb; 79(5-6):770-9. PubMed ID: 10070868
[TBL] [Abstract][Full Text] [Related]
17. Immune reactions induced by interleukin-2 transfected colorectal cancer cells in vitro: predominant induction of lymphokine-activated killer cells.
Lindauer M; Schackert HK; Gebert J; Rudy W; Habicht A; Siebels M; Meuer SC; Moebius U
J Mol Med (Berl); 1996 Jan; 74(1):43-9. PubMed ID: 8834769
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy on renal-cell carcinoma: magic bullet or tragic insanity?
Mickisch GH
World J Urol; 1995; 13(3):178-85. PubMed ID: 7550392
[TBL] [Abstract][Full Text] [Related]
19. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer.
Hathorn RW; Tso CL; Kaboo R; Pang S; Figlin R; Sawyers C; deKernion JB; Belldegrun A
Cancer; 1994 Oct; 74(7):1904-11. PubMed ID: 7521786
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
